PT  - JOURNAL ARTICLE
AU  - Pushpakumara, Pradeep D.
AU  - Jeewandara, Chandima
AU  - Bary, Farha
AU  - Madushanka, Deshan
AU  - Perera, Lahiru
AU  - Aberathna, Inoka Sepali
AU  - Nimasha, Thashmi
AU  - Jayamali, Jeewantha
AU  - Ranasinghe, Thushali
AU  - Kuruppu, Heshan
AU  - Danasekara, Saubhagya
AU  - Wijewickrama, Ananda
AU  - Ogg, Graham S.
AU  - Malavige, Gathsaurie Neelika
TI  - Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals
AID  - 10.1101/2023.01.05.23284247
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.01.05.23284247
4099  - http://medrxiv.org/content/early/2023/01/07/2023.01.05.23284247.short
4100  - http://medrxiv.org/content/early/2023/01/07/2023.01.05.23284247.full
AB  - Background As there are limited data on B cell epitopes for the nucleocapsid protein in SARS-CoV-2, we sought to identify the immunodominant regions within the N protein, recognized by patients with varying severity of natural infection with the Wuhan strain (WT), delta, omicron and in those who received the Sinopharm vaccines, which is an inactivated, whole virus vaccine.Methods Using overlapping peptides representing the N protein, with an in-house ELISA, we mapped the immunodominant regions within the N protein, in seronegative (n=30), WT infected (n=30), delta infected (n=30), omicron infected+vaccinated (n=20) and Sinopharm (BBIBP-CorV) vaccinees (n=30). We then investigated the sensitivity and specificity of these immunodominant regions and analysed their conservation with other SARS-CoV-2 variants of concern, seasonal human coronaviruses and bat Sarbecoviruses. We then investigated the kinetics of responses to these regions in those with varying severity of acute COVID-19.Results We identified four immunodominant regions aa 29-52, aa 155-178, aa 274 to 297 and aa 365 to 388, were highly conserved within SARS-CoV-2 and the bat coronaviruses. The magnitude of responses to these regions varied based on the infecting SARS-CoV-2 variants, with WT infected individuals predominantly recognizing aa155 to 178 regions, delta infected individuals and vaccinated+omicron infected individuals predominantly recognizing regions aa 29 to 52 and aa 274 to 294 regions. Sinopharm vaccinees recognized all four regions, with the magnitude of responses significantly lower than other groups. >80% of individuals gave responses above the positive cut-off threshold to many of the four regions, with some differences with individuals who were infected with different VoCs. These regions were found to be 100% specific, as none of the seronegative individuals gave any responses.Conclusions N-protein specific responses appear to be detectable in over 90% of those who were naturally infected or vaccinated with a whole virus inactivated vaccine, with responses mainly directed against four regions of the protein, which were highly conserved. As these regions were highly specific with high sensitivity, they have a potential to be used to develop diagnostic assays and to be used in development of vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful to Allergy Immunology and Cell Biology Unit, University of Sri Jayewardenepura, the NIH, USA (grant number 5U01AI151788-02), World bank, Sri Lanka Covid 19 Emergency Response and Health Systems Preparedness Project (ERHSP) of Ministry of Health Sri Lanka funded by World Bank and the UK Medical Research Council for funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Blood samples were obtained following informed written consent. Ethics approval was obtained from the Ethics Review Committee of University of Sri Jayewardenepura.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscriptNabsNeutralization antibodiesN proteinNucleocapsid proteinVoCvariants of concernsVNTsurrogate virus neutralizing testRBDreceptor binding domainWTWuhan strain of SARS-CoV-2